AstraZeneca’s clinical Phase IIb study with the drug candidate tremelimumab did not reach the primary target on survival in malignant mesothelioma.
According to a press release.
the study evaluated tremelimumab as monotherapy at a dose of 10 milligrams per kilogram as second or third line treatment.
AstraZeneca stated in the press release that they are disappointed with the study results but that they continued to believe in the compound’s clinical activity when given in combination with other drugs.
Tremelimumab inter alia evaluated in combination with durvalumab against non-small cell lung cancer.
No comments:
Post a Comment